Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is A Study of SPY072 in Rheumatic Disease on October 31, 2026. There are 5 upcoming events on record.
Cash runway is approximately 8.5 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 31, 2026 | A Study of SPY072 in Rheumatic Disease | Trial Milestone | Phase 2 |
| November 18, 2026 | A Study of SPY003-207 in Healthy Volunteers | Trial Milestone | Phase 1 |
| June 15, 2027 | A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | Trial Milestone | Phase 2 |
| October 15, 2027 | A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) | Trial Milestone | Phase 2 |
| March 2, 2029 | Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD | Trial Milestone | Phase 2 |
Track SYRE alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open SYRE in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.